Trial Profile
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 26 Feb 2019 Status changed from recruiting to discontinued as there was lack of enrollment since January 2013
- 13 Feb 2009 New trial record